Homoleptic hexa- and penta-coordinated gallium(I) amide complexes of ruthenium and molybdenum.

Reaction of neutral olefin complexes of ruthenium and molybdenum with GaTMP (TMP = 2,2,6,6-tetramethylpiperidinyl) by substitution leads to the formation of respective five- and six-coordinated homoleptic products. [Ru(GaTMP)5] (1) and [Mo(GaTMP)6] (2) were isolated and characterized. Core structure geometries were analyzed using continuous shape measure, and the complexes were subjected to DFT calculations unveiling competing π-interactions between the transition metal center and the amido substituent with the unoccupied pπ orbitals of the gallium.

Transforming Prior Authorization to Decision Support.

PURPOSE: To evaluate a computer-based prior authorization system that was designed to include and test two new concepts for physician review: (1) the tool would minimize denials by providing real-time decision support with alternative options if the original request was noncompliant, and (2) the tool would collect sufficient information to create a patient registry. METHODS: A new prior authorization tool incorporating real-time decision support was tested with a large national payer. The tool used the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology as the content for decision making. Physicians were asked to submit the minimal amount of clinical data necessary to reach a treatment-decision node within the National Comprehensive Cancer Network Guidelines. To minimize denials, all available recommended treatments were displayed for physician consideration and immediate authorization was granted for any compliant selection. RESULTS: During a 1-year pilot in a Florida commercial health plan, 4,272 eligible cases were reviewed with only 42 denials. Chemotherapy drug costs for the prior authorization pilot were compared with a similar time period in the previous year for the state of Florida, as well as for the Southeast region and for the nation, which served as controls. The percentage change between the time periods was -9% in Florida, 10% for the national costs, and 11% for the Southeast region costs. The difference between the regional increase and the Florida decrease represented a savings of $5.3 million dollars for the state of Florida in 1 year. CONCLUSION: There is significant opportunity to reduce the costs of therapy while being compliant with nationally accepted guidelines for cancer chemotherapy.